1. Preface 

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Research Methodology 

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot

4. Market Overview

    4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview 

    4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments

    4.3. Market Dynamics

    4.4. Drivers and Restraints Snapshot Analysis

    4.5. Drivers

        4.5.1. Fast track and orphan drug designations

        4.5.2. Increase in strategic collaboration among key players

    4.6. Restraints

        4.6.1. Side-effects and risks related to drug usage

        4.6.2. Stringent regulatory requirements

    4.7. Opportunities

    4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario by Region/Country

    5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)

    5.4. Prevalence of Liver & Kidney Diseases by Region/Globally

6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

    6.1. Introduction

    6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        6.2.1. Type 1 Hepatorenal Syndrome

        6.2.2. Type 2 Hepatorenal Syndrome

    6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

    6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type

7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

    7.1. Introduction

    7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        7.2.1. Therapeutics

            7.2.1.1. Terlivaz

            7.2.1.2. Glypressin

            7.2.1.3. Lucassin 

            7.2.1.4. Hepatoren

        7.2.2. Surgical Treatment

            7.2.2.1. Liver Transplantation

            7.2.2.2. Surgical Shunting

                7.2.2.2.1. Peritoneovenous Shunting

                7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                7.2.2.2.3. Others

            7.2.2.3. Renal Replacement Therapy

            7.2.2.4. Others

    7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

    7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment

8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

    8.1. Introduction

    8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        8.2.1. Hospitals & Clinics

        8.2.2. Ambulatory Surgical Centers

        8.2.3. Academic & Research Institutes

        8.2.4. Others

    8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

    8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user

9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

    9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017–2027 

        9.1.1. North America

        9.1.2. Europe

        9.1.3. Asia Pacific

        9.1.4. Latin America

        9.1.5. Middle East & Africa

    9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

    9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region

10. North America Hepatorenal Syndrome Treatment Market Analysis

    10.1. North America Hepatorenal Syndrome Treatment Market 

    10.2. North America Hepatorenal Syndrome Treatment Market Overview

    10.3. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        10.3.1. Type 1 Hepatorenal Syndrome

        10.3.2. Type 2 Hepatorenal Syndrome

    10.4. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        10.4.1. Therapeutics

            10.4.1.1. Terlivaz

            10.4.1.2. Glypressin

            10.4.1.3. Lucassin 

            10.4.1.4. Hepatoren

        10.4.2. Surgical Treatment

            10.4.2.1. Liver Transplantation

            10.4.2.2. Surgical Shunting

                10.4.2.2.1. Peritoneovenous Shunting

                10.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                10.4.2.2.3. Others

            10.4.2.3. Renal Replacement Therapy

        10.4.3. Others

    10.5. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        10.5.1. Hospitals & Clinics

        10.5.2. Ambulatory Surgical Centers

        10.5.3. Academic & Research Institutes

        10.5.4. Others

    10.6. North America Hepatorenal Syndrome Treatment Market Forecast, by Country

        10.6.1. U.S.

        10.6.2. Canada

    10.7. North America Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        10.7.1. By Type

        10.7.2. By Treatment

        10.7.3. By End-user

        10.7.4. By Country

11. Europe Hepatorenal Syndrome Treatment Market Analysis

    11.1. Europe Hepatorenal Syndrome Treatment Market 

    11.2. Europe Hepatorenal Syndrome Treatment Market Overview

    11.3. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        11.3.1. Type 1 Hepatorenal Syndrome

        11.3.2. Type 2 Hepatorenal Syndrome

    11.4. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        11.4.1. Therapeutics

            11.4.1.1. Terlivaz

            11.4.1.2. Glypressin

            11.4.1.3. Lucassin 

            11.4.1.4. Hepatoren

        11.4.2. Surgical Treatment

            11.4.2.1. Liver Transplantation

            11.4.2.2. Surgical Shunting

                11.4.2.2.1. Peritoneovenous Shunting

                11.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                11.4.2.2.3. Others

            11.4.2.3. Renal Replacement Therapy

        11.4.3. Others

    11.5. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        11.5.1. Hospitals & Clinics

        11.5.2. Ambulatory Surgical Centers

        11.5.3. Academic & Research Institutes

        11.5.4. Others

    11.6. Europe Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        11.6.1. U.K.

        11.6.2. France

        11.6.3. Germany

        11.6.4. Spain

        11.6.5. Italy

        11.6.6. Rest of Europe

    11.7. Europe Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        11.7.1. By Type

        11.7.2. By Treatment

        11.7.3. By End-user

        11.7.4. By Country/Sub-region

12. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis

    12.1. Asia Pacific Hepatorenal Syndrome Treatment Market Key Findings

    12.2. Asia Pacific Hepatorenal Syndrome Treatment Market Overview

    12.3. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        12.3.1. Type 1 Hepatorenal Syndrome

        12.3.2. Type 2 Hepatorenal Syndrome

    12.4. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        12.4.1. Therapeutics

            12.4.1.1. Terlivaz

            12.4.1.2. Glypressin

            12.4.1.3. Lucassin 

            12.4.1.4. Hepatoren

        12.4.2. Surgical Treatment

            12.4.2.1. Liver Transplantation

            12.4.2.2. Surgical Shunting

                12.4.2.2.1. Peritoneovenous Shunting

                12.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                12.4.2.2.3. Others

            12.4.2.3. Renal Replacement Therapy

        12.4.3. Others

    12.5. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        12.5.1. Hospitals & Clinics

        12.5.2. Ambulatory Surgical Centers

        12.5.3. Academic & Research Institutes

        12.5.4. Others

    12.6. Asia Pacific Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        12.6.1. China

        12.6.2. India

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        12.7.1. By Type

        12.7.2. By Treatment

        12.7.3. By End-user

        12.7.4. By Country/Sub-region

13. Latin America Hepatorenal Syndrome Treatment Market Analysis

    13.1. Latin America Hepatorenal Syndrome Treatment Market Key Findings

    13.2. Latin America Hepatorenal Syndrome Treatment Market Overview

    13.3. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        13.3.1. Type 1 Hepatorenal Syndrome

        13.3.2. Type 2 Hepatorenal Syndrome

    13.4. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        13.4.1. Therapeutics

            13.4.1.1. Terlivaz

            13.4.1.2. Glypressin

            13.4.1.3. Lucassin 

            13.4.1.4. Hepatoren

        13.4.2. Surgical Treatment

            13.4.2.1. Liver Transplantation

            13.4.2.2. Surgical Shunting

                13.4.2.2.1. Peritoneovenous Shunting

                13.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                13.4.2.2.3. Others

            13.4.2.3. Renal Replacement Therapy

        13.4.3. Others

    13.5. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        13.5.1. Hospitals & Clinics

        13.5.2. Ambulatory Surgical Centers

        13.5.3. Academic & Research Institutes

        13.5.4. Others

    13.6. Latin America Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Latin America Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        13.7.1. By Type

        13.7.2. By Treatment

        13.7.3. By End-user

        13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatorenal Syndrome Treatment Market Analysis

    14.1. Middle East & Africa Hepatorenal Syndrome Treatment Market 

    14.2. Middle East & Africa Hepatorenal Syndrome Treatment Market Overview

    14.3. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        14.3.1. Type 1 Hepatorenal Syndrome

        14.3.2. Type 2 Hepatorenal Syndrome

    14.4. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        14.4.1. Therapeutics

            14.4.1.1. Terlivaz

            14.4.1.2. Glypressin

            14.4.1.3. Lucassin 

            14.4.1.4. Hepatoren

        14.4.2. Surgical Treatment

            14.4.2.1. Liver Transplantation

            14.4.2.2. Surgical Shunting

                14.4.2.2.1. Peritoneovenous Shunting

                14.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                14.4.2.2.3. Others

            14.4.2.3. Renal Replacement Therapy

        14.4.3. Others

    14.5. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        14.5.1. Hospitals & Clinics

        14.5.2. Ambulatory Surgical Centers

        14.5.3. Academic & Research Institutes

        14.5.4. Others

    14.6. Middle East & Africa Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        14.7.1. By Type

        14.7.2. By Treatment

        14.7.3. By End-user

        14.7.4. By Country/Sub-region

15. Competitive Landscape 

    15.1. Company Profiles

        15.1.1. Cumberland Pharmaceuticals, Inc.

            15.1.1.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.1.2. Financials

            15.1.1.3. Recent Developments

            15.1.1.4. Strategy

        15.1.2. Orphan Therapeutics, LLC. 

            15.1.2.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.2.2. Financials

            15.1.2.3. Recent Developments

            15.1.2.4. Strategy

        15.1.3. BioVie Inc.

            15.1.3.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.3.2. Financials

            15.1.3.3. Recent Developments

            15.1.3.4. Strategy

        15.1.4. Mallinckrodt Pharmaceuticals 

            15.1.4.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.4.2. Financials

            15.1.4.3. Recent Developments

            15.1.4.4. Strategy

List of Tables

TABLE 1 Global Hepatorenal Syndrome Treatment Pipeline Analysis (1/5)

TABLE 2 Global Hepatorenal Syndrome Treatment Pipeline Analysis (2/5)

TABLE 3 Global Hepatorenal Syndrome Treatment Pipeline Analysis (3/5)

TABLE 4 Global Hepatorenal Syndrome Treatment Pipeline Analysis (4/5)

TABLE 5 Global Hepatorenal Syndrome Treatment Pipeline Analysis (5/5)

TABLE 6 Comparative Analysis of Orphan Drug Policies

TABLE 7 Worldwide Epidemiology of Liver Diseases 

TABLE 8 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 9 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 10 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 11 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 12 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 13 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 14 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

TABLE 15 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

TABLE 16 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 17 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 18 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 19 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 20 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 21 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 22 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 23 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 24 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 25 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 26 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 27 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 28 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 29 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 30 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 31 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 32 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 33 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 34 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 35 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 36 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 37 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 38 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 39 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 40 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 41 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 42 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 46 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 47 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 48 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 49 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

FIG. 1 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

FIG. 2 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type (2018)

FIG. 3 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment (2018)

FIG. 4 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user (2018)

FIG. 5 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region (2018)

FIG. 6 Regulatory Approval Process - U.S.  

FIG. 7 Regulatory Approval Process - Europe 

FIG. 8 Regulatory Approval Process - Japan

FIG. 9 Regulatory Approval Process - China

FIG. 10 Revision of Drug Administration Law & Drug Registration Regulation

FIG. 11 Drug Approval Process in China - Step 1

FIG. 12 Drug Approval Process in China - Step 2

FIG. 13 Drug Approval Process in China - Step 3

FIG. 14 Recent CFDA Regulatory Reforms to Support Innovative Drugs

FIG. 15 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type, 2018 and 2027

FIG. 16 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Type, 2019–2027

FIG. 17 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 1 Hepatorenal Syndrome, 2017–2027

FIG. 18 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 2 Hepatorenal Syndrome, 2017–2027

FIG. 19 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment, 2018 and 2027

FIG. 20 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Treatment, 2019–2027

FIG. 21 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Therapeutics, 2017–2027

FIG. 22 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Treatment, 2017–2027

FIG. 23 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user, 2018 and 2027

FIG. 24 Global Hepatorenal Syndrome Treatment Market Attractiveness, by End-user, 2019–2027

FIG. 25 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics, 2017–2027

FIG. 26 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027

FIG. 27 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic & Research Institutes, 2017–2027

FIG. 28 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

FIG. 29 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region, 2018 and 2027

FIG. 30 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Region, 2019–2027

FIG. 31 North America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 32 North America Hepatorenal Syndrome Treatment Market Value Share (%), by Country, 2018 and 2027

FIG. 33 North America Hepatorenal Syndrome Treatment Market Attractiveness, by Country, 2019–2027

FIG. 34 Europe Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 35 Europe Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 36 Europe Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 37 Asia Pacific Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 38 Asia Pacific Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 39 Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 40 Latin America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 41 Latin America Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 42 Latin America Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 46 Cumberland Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

FIG. 47 Cumberland Pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2018

FIG. 48 Mallinckrodt Pharmaceuticals, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

FIG. 49 Mallinckrodt Pharmaceuticals, R&D Expenses, 2015–2018

FIG. 50 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Region, 2018

FIG. 51 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Business Segment, 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Hepatorenal Syndrome Treatment Market

Buy Now